International Journal of Hematology

DOI: 10.1007/s12185-017-2369-z Pages: 123-124

Correction to: Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations

1. Nara Medical University, Department of Pediatrics

2. Tokyo Medical University Hospital, Department of Laboratory Medicine

3. Hiroshima University Hospital, Department of Hematology and Oncology

4. St. Marianna University School of Medicine, Department of Pediatrics

5. Nagoya University Hospital, Department of Transfusion Medicine

6. Hyogo College of Medicine Hospital, Division of Hematology

7. University of Occupational and Environmental Health, Department of Pediatrics

8. Munakata Suikokai General Hospital, Department of Pediatrics

9. Baxalta Japan Ltd., Department of Medical Affairs

10. Baxalta Japan Ltd., Department of Clinical Development Operations

11. Shire

12. University of Washington School of Medicine, Puget Sound Blood Center

Correspondence to:
Keiji Nogami



The authors would like to correct the error in Table 2 in the original publication of the article. The “Blood type” is not described in any part of “Results” and “Discussion” and had no impact on the conclusion hence the bottom of the table is removed.

This article is freely available, click here to access the full text/PDF

Share the Knowledge